view transcript

Jessica Billingsley: We are very interested in providing meaningful insights with our data. So a piece of a current strategy moving forward, will absolutely be data analytics.

Debra Borchardt: And let's go into that. Tell me what types of things we could do with this data. What kind of data are you talking about?

Jessica Billingsley: Ultimately.. So you could have the most data in the world and it's really what questions are you trying to answer? So questions like who is the cannabis consumer? What is the fastest growing segment of consumers, which is women over 50, by the way? You know..

Debra Borchardt: Just sayin'..

Jessica Billingsley: Also interesting, our data's been able to track the relationship between adult use and medical markets. So there's this, I think misconception that when that this is a progression that a state passes medical and then they pass adult use and then that's, that medical goes away, right? Our data doesn't show that to be true. Our data shows that over a six month period of time after adult use is passed in particular market, medical use begins to climb symbiotically with adult use as well in the market. Which really says to me that many people are coming to cannabis for health and wellness needs.

Debra Borchardt: With CBD, what we see in the adult use arena of CBD is a fairly low CBD component. You tend to need a higher level of CBD then as it's not the kind of CBD you're finding at the CVS right now. You really do need a prescription level CBD or you need a CBD that is not going to be found and just a basic over the counter product. Correct?

Jessica Billingsley: There are over 400 identified cannabinoids in cannabis. We talk a lot about THC and CBD. I think we will see beyond CBD here soon and they're generally most efficacious when it's a full spectrum distillation. So when you have all the little bits, and you have isolated out, only this one compound, you experience the entourage effect of, you know, maybe you need a lower prescription of CBD if you have just a teeny tiny bit of all those other little canabinoids in there as well.

Akerna (KERN) the pot-tech company that made its trading debut Tuesday, June 17th on the Nasdaq is on a tear. At one point, the stock jumped more than 100%.

CEO Jessica Billingsley told TheStreet in an exclusive video Webinar "This is a wonderful milestone, but it's [only] the beginning," she said in a half-hour exclusive interview with TheStreet's cannabis columnist Debra Borchardt. "I'm excited about what we can do with a larger opportunity -- with public currency -- and especially as the global market is growing so quickly, I'm really excited about the types of problems that we can solve." 

So, what are those problems they plan to solve?

Billingsley said, "...you can have the most data in the world, and it's really what questions are you trying to answer? So, questions like, who is the cannabis consumer? What is the fastest growing segment of consumers, which is women over 50, by the way..."

Watch an excerpt from TheStreet's exclusive webinar above, or watch the entire interview here: FREE WEBINAR: CEO of Hot Cannabis Stock Akerna Talks to TheStreet

Related: How the Cannabis Tech Company Akerna Is Changing the Industry